JP Morgan Rates Lexeo Therapeutics (LXEO) buy, $9 Price Target
JP Morgan maintains its buy rating on Lexeo Therapeutics, Inc., setting a target price of $9, a 89.47% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
JP Morgan rated Lexeo Therapeutics, Inc. ($LXEO) "buy" with a $9 price target on June 25, 2026.
Since the rating, $LXEO is down 0.2% after 1 week, down 4.9% after 1 month and down 43.8% to date (from the $4.70 close on Jun 25, 2026).
LXEO
Lexeo Therapeutics, Inc.
Key Points
- JP Morgan reiterated its buy rating on Lexeo Therapeutics, Inc. with a target price of $9 on June 25, 2026.
- JP Morgan's $9 price target implies 89.47% upside from Lexeo Therapeutics, Inc.'s ($LXEO) current $4.75 share price.
- Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) shares traded near $4.89 on Thursday, with a 52-week range of $3.60 to $10.99.
- Insider activity includes multiple transactions by executives, with recent analyst ratings highlighting a strong buy consensus.
Get $LXEO trade alerts by text
We text you when insiders, Congress or big funds trade $LXEO. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Lexeo Therapeutics, Inc. alert may contain errors. Disclosures
JP Morgan reiterated its buy rating on Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) on June 25, 2026. The financial firm set a target price of $9 for the biotechnology company, which focuses on genetic medicine. Shares of Lexeo traded near $4.89 on Thursday, reflecting investor interest in the company's potential.
JP Morgan vs. the S&P 500
Hypothetical returns from JP Morgan's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Lexeo Therapeutics
Several institutional investors have made moves in Lexeo Therapeutics recently. Paradigm Biocapital Advisors LP increased its holdings by 1,420,936 shares, ending with 6,184,134 shares valued at about $35.5 million. BlackRock, Inc. added 203,308 shares, bringing its total to 5,110,871 shares worth approximately $29.3 million. Affinity Asset Advisors, LLC significantly boosted its stake by 1,850,211 shares, holding 5,050,211 shares valued at $28.9 million. Meanwhile, Janus Henderson Group PLC trimmed its position by 533,206 shares, leaving it with 4,976,429 shares worth about $28.5 million.
Lexeo Therapeutics, Inc. Stock Up 13.1%
On Thursday, shares of Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) traded near $4.89. The company has a market cap of approximately $395.7 million. Lexeo's stock has a 52-week low of $3.60 and a high of $10.99, with a 50-day moving average of $5.43 and a 200-day moving average of $7.15. The company is not currently profitable, resulting in no meaningful forward P/E ratio. Lexeo's beta is 1.389, indicating some volatility compared to the market.
$LXEO price target
Lexeo Therapeutics, Inc. daily closes and this analyst's $9 target. Not advice.
Insider Buying and Selling at Lexeo Therapeutics, Inc.
Recent insider activity at Lexeo Therapeutics includes several transactions. On May 18, 2026, Chief Operating Officer Jose Manuel Otero sold 1,302 shares at an average price of $5.07. On the same day, CEO Richard Nolan Townsend sold 3,342 shares at $5.06. Earlier, on April 6, 2026, Townsend sold 55,000 shares at $5.69 under a planned transaction. Conversely, on March 13, 2026, Townsend purchased 2,623 shares at $2.64, while Otero bought 5,930 shares at the same price.
Analysts Set New Price Targets
On June 25, 2026, JP Morgan maintained its buy rating for Lexeo Therapeutics with a $9 target price. Earlier, on May 11, 2026, Chardan Capital also maintained a buy rating with a $17 target. HC Wainwright & Co. and Raymond James have also shown positive outlooks, with targets of $10 and $25, respectively. The consensus among analysts is a strong buy, with a mean target price of $20.9 from ten opinions.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a biotechnology company based in New York, New York. It focuses on developing genetic medicine for hereditary and acquired diseases with high unmet needs. The company has a robust pipeline, including candidates for conditions like Friedreich ataxia cardiomyopathy and Alzheimer's disease. Founded in 2017, Lexeo employs about 59 people and is led by CEO Mr. R. Nolan Townsend.
Bottom Line
JP Morgan's reiterated buy rating and $9 target reflect confidence in Lexeo Therapeutics' potential in genetic medicine. Investors are watching the company's progress closely, especially given its focus on high-need areas like cardiomyopathy and Alzheimer's. As with all 13F filings and analyst reports, remember these insights are backward-looking and may not represent current positions or future performance.
Related Filing Alerts
Source: JP Morgan's rating change on $LXEO (Jun 25, 2026). Written by software, not financial advice. How we make alerts